The Irradiation Facility at Fox Chase Cancer Center (FCCC) manages the shared use of ionizing radiation sources according to procedures mandated in our license from the Nuclear Regulatory Commission (NRC). Management and maintenance of these potentially dangerous, costly devices ($100,000-$200,000 each) as a shared resource for multiple users facilitates administration, quality assurance, safety and regulatory compliance. The Facility consists of two different irradiators, each sited optimally for its specific use. They produce fields of Cesium-137 gamma-rays to irradiate molecules in solution, cell cultures, rodent tumors or normal tissues for studies of radiobiologic mechanisms, to suppress immune response, to induce DMA damage and/or mitotic arrest, and to sterilize cell and drug preparations. The Shepherd Model 280 irradiator is situated in the Laboratory Animal Facility and used mainly for whole body irradiation of animals used in immunobiology research (see Hayakawa et al., J. Exp. Med. 197:87-99, 2003;Allman et al., J. Immunol. 167:6834-6840, 2001). The panoramic Shepherd Model 81-14R irradiator is situated in the basement of the Reimann Building. It was used 223 times in 2003 primarily for the irradiation of cells (see, for example, Katz et al., J. Virol. 76:5422-5434, 2002;Mu et al., Int. J. Radiat. Oncol. Biol. Phys. 58:336-343, 2004). Oversight of Facility operation is provided by the Facility Manager, Facility Director, Radiation Safety Officer, Radiation Safety Committee, FCCC Administration and the NRC. Facility staff operate various radiation dosimeters to accurately determine the dose to experimental set-ups and is available to FCCC investigators for planning radiation experiments, to assist infrequent users, for training individuals to become qualified irradiator users in accord with NRC and other safety regulations and for overseeing the annual maintenance and quality assurance of equipment. Inventories of the radioactive sources are made at intervals determined by the Homeland Security threat level. Over the last Core grant cycle, the Facility was used by 24 peer-reviewed funded investigators from ten FCCC research Programs in two Center Divisions. Currently, 92% of Facility use is by peer-reviewed funded investigators. Facility use has increased about 10% per year and is projected to increase 5-10% per year during the next Core grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-47
Application #
7881784
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
47
Fiscal Year
2009
Total Cost
$64,481
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Auerbach, M V; Heckman, C J; Darlow, S (2018) To protect or not to protect: examining reasons for sun protection among young women at risk for skin cancer. J Behav Med 41:528-536
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886

Showing the most recent 10 out of 1280 publications